Published :
Tables : 49
Figures : 44
Category : Healthcare
No. of Pages : 226
Report Code : HC-U3384
Ankylosing Spondylitis Market Ois poised to register a CAGR of 4.6% during the forecast period 2022 to 2028. The emergence of advanced products like biosimilars is the key factor responsible for the ankylosing spondylitis market growth. Furthermore, the growing prevalence of spondylitis owing to increased usage of smart phones, laptops and other electronic devices that enforce a strain on the spinal cord, lack of exercise and a sedentary lifestyle shall bolster the proliferation of the market. As per the data provided by the Oxford University Press, the number of patients in the European region have risen to over 1.5 million and over 4 million in the Asia Pacific region, with such a prevalence of spondylitis, the market is predicted to lead the market during the forecasted timeframe. Major players included in the Ankylosing Spondylitis Market: • AbbVie Inc. • Janssen Pharmaceuticals Inc. • Pfizer Inc. • Sandoz International GmbH. • Amgen Inc. • Protalix BioTherapeutics, Inc. • Reliance Life Sciences Pvt. Ltd. • Momenta Pharmaceuticals Inc. • Celgene Corporation • Regeneron Pharmaceuticals • Merck & Co. Inc. • Johnson & Johnson Services, Inc. • UCB Inc. • Eli Lilly and Company • Novartis AG • Samsung Bioepis Co., Ltd. • Biothera Pharmaceuticals, Inc (Note: The list of the major players will be updated with the latest market scenario and trends) Ankylosing Spondylitis Market Segmentation: By Drug • Cosentyx • Humira • Simponi • Remicade • Embrel • Cimzia By Molecule Type • Small Molecules • Biologics • Biosimilars By Route of Administration • Oral • Parenteral By End User • Hospitals • Clinics • Others By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa The market is categorized into drug, molecule type, route of administration, end user and region. The drug segment is fragmented into Cosentyx, Humira, Simponi, Enbrel and Cimzia. The Humira drug is estimated to hold the largest ankylosing spondylitis market share and this is credited to its high efficacy and low cost. The Cosentyx, however, it predicted to grow at a substantial rate during the forecasted timeframe owing to the expiration of patents in the European region. The end user segment is classified into hospitals, clinics and others. Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Ankylosing Spondylitis Market By Drug, By Molecule Type, By Route of Administration, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers, and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The emergence of advanced products like biosimilars is the key factor responsible for the ankylosing spondylitis market growth. Furthermore, the growing prevalence of spondylitis owing to increased usage of smart phones, laptops and other electronic devices that enforce a strain on the spinal cord, lack of exercise and a sedentary lifestyle shall bolster the proliferation of the market. As per the data provided by the Oxford University Press, the number of patients in the European region have risen to over 1.5 million and over 4 million in the Asia Pacific region, with such a prevalence of spondylitis, the market is predicted to lead the market during the forecasted timeframe.
Major players included in the Ankylosing Spondylitis Market:
• AbbVie Inc. • Janssen Pharmaceuticals Inc. • Pfizer Inc. • Sandoz International GmbH. • Amgen Inc. • Protalix BioTherapeutics, Inc. • Reliance Life Sciences Pvt. Ltd. • Momenta Pharmaceuticals Inc. • Celgene Corporation • Regeneron Pharmaceuticals • Merck & Co. Inc. • Johnson & Johnson Services, Inc. • UCB Inc. • Eli Lilly and Company • Novartis AG • Samsung Bioepis Co., Ltd. • Biothera Pharmaceuticals, Inc (Note: The list of the major players will be updated with the latest market scenario and trends)
Ankylosing Spondylitis Market Segmentation:
By Drug • Cosentyx • Humira • Simponi • Remicade • Embrel • Cimzia
By Molecule Type • Small Molecules • Biologics • Biosimilars By Route of Administration • Oral • Parenteral
By End User • Hospitals • Clinics • Others
By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa
The market is categorized into drug, molecule type, route of administration, end user and region. The drug segment is fragmented into Cosentyx, Humira, Simponi, Enbrel and Cimzia. The Humira drug is estimated to hold the largest ankylosing spondylitis market share and this is credited to its high efficacy and low cost. The Cosentyx, however, it predicted to grow at a substantial rate during the forecasted timeframe owing to the expiration of patents in the European region. The end user segment is classified into hospitals, clinics and others.
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Ankylosing Spondylitis Market By Drug, By Molecule Type, By Route of Administration, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers, and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Molecule Typeology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Ankylosing Spondylitis Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Ankylosing Spondylitis Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Ankylosing Spondylitis Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Ankylosing Spondylitis Market,By Drug Historical Analysis and Forecast 2022-2028 (USD Million) 7.1 Cosentyx 7.2 Humira 7.3 Simponi 7.4 Remicade 7.5 Embrel 7.6 Cimzia 8. Ankylosing Spondylitis Market, By Molecule Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Small Molecules 8.2. Biologics 8.3. Biosimilars 9. Ankylosing Spondylitis Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Oral 9.2. Parenteral 10. Ankylosing Spondylitis Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Hospitals 10.2. Clinics 10.3. Others 11. North America Ankylosing Spondylitis Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028 12. Latin America Ankylosing Spondylitis Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028 13. Europe Ankylosing Spondylitis Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028 14. Asia Pacific Ankylosing Spondylitis Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 15. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Drugs Offered and Financial Layouts) 17.1. AbbVie Inc. 17.1.1. Company Overview 17.1.2. Drug Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Janssen Pharmaceuticals Inc. 17.2.1. Company Overview 17.2.2. Drug Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Pfizer Inc. 17.3.1. Company Overview 17.3.2. Drug Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Sandoz International GmbH. 17.4.1. Company Overview 17.4.2. Drug Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Amgen Inc. 17.5.1. Company Overview 17.5.2. Drug Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Protalix BioTherapeutics, Inc. 17.6.1. Company Overview 17.6.2. Drug Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Reliance Life Sciences Pvt. Ltd. 17.7.1. Company Overview 17.7.2. Drug Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Momenta Pharmaceuticals Inc. 17.8.1. Company Overview 17.8.2. Drug Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Celgene Corporation 17.9.1. Company Overview 17.9.2. Drug Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Regeneron Pharmaceuticals 17.10.1. Company Overview 17.10.2. Drug Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Merck & Co. Inc. 17.11.1. Company Overview 17.11.2. Technology Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Johnson & Johnson Services, Inc. 17.12.1. Company Overview 17.12.2. Technology Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.UCB Inc. 17.13.1. Company Overview 17.13.2. Technology Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14.Novartis AG 17.14.1. Company Overview 17.14.2. Technology Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15.Samsung Bioepis Co., Ltd. 17.15.1. Company Overview 17.15.2. Technology Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview 17.16.Biothera Pharmaceuticals, Inc. 17.16.1. Company Overview 17.16.2. Technology Portfolio 17.16.3. SWOT Analysis 17.16.4. Financial Overview 17.16.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders
2. Research Molecule Typeology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study
3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights
4. Ankylosing Spondylitis Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Ankylosing Spondylitis Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Ankylosing Spondylitis Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Ankylosing Spondylitis Market,By Drug Historical Analysis and Forecast 2022-2028 (USD Million) 7.1 Cosentyx 7.2 Humira 7.3 Simponi 7.4 Remicade 7.5 Embrel 7.6 Cimzia
8. Ankylosing Spondylitis Market, By Molecule Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Small Molecules 8.2. Biologics 8.3. Biosimilars
9. Ankylosing Spondylitis Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Oral 9.2. Parenteral
10. Ankylosing Spondylitis Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Hospitals 10.2. Clinics 10.3. Others
11. North America Ankylosing Spondylitis Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028
12. Latin America Ankylosing Spondylitis Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028
13. Europe Ankylosing Spondylitis Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028
14. Asia Pacific Ankylosing Spondylitis Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
15. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028
16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Drugs Offered and Financial Layouts) 17.1. AbbVie Inc. 17.1.1. Company Overview 17.1.2. Drug Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Janssen Pharmaceuticals Inc. 17.2.1. Company Overview 17.2.2. Drug Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Pfizer Inc. 17.3.1. Company Overview 17.3.2. Drug Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Sandoz International GmbH. 17.4.1. Company Overview 17.4.2. Drug Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Amgen Inc. 17.5.1. Company Overview 17.5.2. Drug Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Protalix BioTherapeutics, Inc. 17.6.1. Company Overview 17.6.2. Drug Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Reliance Life Sciences Pvt. Ltd. 17.7.1. Company Overview 17.7.2. Drug Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Momenta Pharmaceuticals Inc. 17.8.1. Company Overview 17.8.2. Drug Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Celgene Corporation 17.9.1. Company Overview 17.9.2. Drug Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Regeneron Pharmaceuticals 17.10.1. Company Overview 17.10.2. Drug Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Merck & Co. Inc. 17.11.1. Company Overview 17.11.2. Technology Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Johnson & Johnson Services, Inc. 17.12.1. Company Overview 17.12.2. Technology Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.UCB Inc. 17.13.1. Company Overview 17.13.2. Technology Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14.Novartis AG 17.14.1. Company Overview 17.14.2. Technology Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15.Samsung Bioepis Co., Ltd. 17.15.1. Company Overview 17.15.2. Technology Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview 17.16.Biothera Pharmaceuticals, Inc. 17.16.1. Company Overview 17.16.2. Technology Portfolio 17.16.3. SWOT Analysis 17.16.4. Financial Overview 17.16.5. Strategic Overview
18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics